ApconiX Welcomes Dr Karen Jones to The Team.

ApconiX is delighted to welcome Dr Karen Jones who joins us from AstraZeneca.  Karen, a talented electrophysiologist, will work with Dr Michael Morton to ensure the laboratory continues to provide an outstanding service as the demand for ion channel and cardiovascular safety screening increases.

Karen graduated from the University of Liverpool with a degree in Pharmacology.  After researching the basis for naphthoquinone and biguanide synergy, Karen gained her PhD from the University of Liverpool.  Karen worked at Astra Zeneca for some 14 years, most recently as project lead for multiple high throughput screening campaigns supporting projects in a range of disease areas including Neuroscience, Oncology, Cardiovascular and Metabolic disease.

Mike couldn’t be more pleased with the new member of the team, “In addition to her electrophysiology background, Karen brings Big Pharma expertise in high throughput screening and Genedata to ApconiX that adds to our future capability”.

“Experienced, flexible scientists are at the heart of the service we provide to our customers as we continue to shape and grow the European Centre of Excellence for preclinical cardiovascular electrophysiology.”

By |2018-07-11T14:36:29+00:00December 2nd, 2017|Ion Channels, Careers|Comments Off on ApconiX Welcomes Dr Karen Jones to The Team.

About the Author:

Dr Michael Morton, PhD, Director and Cofounder, ApconiX, UK, an integrated toxicology and ion channel company that brings together a team of world-renowned nonclinical safety experts with over 400 years of drug discovery and development experience. Mike graduated from the University of Wolverhampton with a degree in Biomedical Sciences and then aspiration to work in hospital pathology. Having finished his Sandwich placement in Clinical Biochemistry at Sandwell Hospital and Mike subsequently gained a MSc in Clinical Biochemistry from the University of Manchester and carried out research into porphyrin metabolism. Moving to the University of Leeds, Mike completed his PhD in Pharmacology at researching adenosine receptor expression in the rat kidney . Mike was introduced to ion channels as a Post-Doc at Leeds and Yale University, patching with the likes of Fred Sigworth and Steve Hebert, then joined the Global Ion Channel Initiative at AstraZeneca. Mike worked at AstraZeneca for eight years before founding ApconiX with Professor Ruth Roberts and Dr Richard Knight. Mike has a serious passion for ion channels. And he’s very good at them . He is a serious scientist (with a serious sense of humour) who wants to make sure that every customer understands the consequences of the results he obtains and works with his colleagues to ensure a better decision is made on drug safety.